Andrew Kang is a Principal at ClearView Healthcare Partners, a strategy consulting firm focused on the life sciences industry. He has extensive experience collaborating with clients across a diverse spectrum of strategic engagements involving asset-, disease-, and therapeutic area-level growth strategy, as well as pipeline and portfolio prioritization and strategy. He has worked across all major therapeutic areas, with recent focus in neurology, immunology, and vaccines. Prior to joining ClearView, Dr. Kang received his PhD in biomedical engineering from Columbia University, where his research focused on predicting the functional consequences of traumatic brain injury and novel drug delivery approaches. While at Columbia, he was a Fellow at Columbia Technology Ventures, where he assessed the commercial potential of early-stage innovation within the life sciences. Dr. Kang previously received an MS in biomedical engineering from Columbia University and a BS in biochemistry from the University of Iowa.